Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?
作者信息
Chen C, Vlasses P H
机构信息
University Health System Consortium, Oak Brook, IL 60523, USA.
出版信息
Am Heart J. 1999 May;137(5):S71-4. doi: 10.1016/s0002-8703(99)70433-3.
Abstract
摘要
相似文献
1
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?
Am Heart J. 1999 May;137(5):S71-4. doi: 10.1016/s0002-8703(99)70433-3.
2
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
Am Heart J. 1999 May;137(5):S67-70. doi: 10.1016/s0002-8703(99)70432-1.
3
Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
Am Heart J. 1999 May;137(5):S62-6. doi: 10.1016/s0002-8703(99)70431-x.
4
5
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
Am Heart J. 1999 May;137(5):S47-50. doi: 10.1016/s0002-8703(99)70428-x.
6
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis.
Am Heart J. 1999 May;137(5):S38-40. doi: 10.1016/s0002-8703(99)70426-6.
7
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
Am Heart J. 1999 May;137(5):S111-4. doi: 10.1016/s0002-8703(99)70442-4.
8
Improving the health of the American public requires a broad research agenda.
Acad Med. 1999 May;74(5):530-1. doi: 10.1097/00001888-199905000-00020.
9
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
Am Heart J. 1999 May;137(5):S41-6. doi: 10.1016/s0002-8703(99)70427-8.
10
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
Am Heart J. 1999 May;137(5):S51-2. doi: 10.1016/s0002-8703(99)70429-1.
引用本文的文献
1
Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making.
Pharmacoeconomics. 2002;20(1):9-21. doi: 10.2165/00019053-200220010-00002.
Zotero 插件